We help you understanding patient needs with a customized mix of approaches.
Our greatest passion is learning from patients and partnering with them to capture and share their expertise with professionals in the healthcare system, in particular industry, payers, and HCPs. With every project, our goal is co-creating solutions that benefit both patients and industry.
For the European Medicines Agency to maintain the Orphan Drug Designation, data was necessary to evaluate the use and access to mexiletine across Europe. There is limited data on the impact of and disrupted availability of mexiletine in the EU.
A client wishes to submit an HTA dossier to a payer institution for a therapeutic indication with many other approved treatments.